| 期 |
栏目 |
标题 |
文件 |
| 卷 15, 编号 3 (2013) |
Articles |
Bevatsizumab v kombinatsii s khimioterapiey pri rake molochnoy zhelezy |
|
| 卷 21, 编号 2 (2019) |
Articles |
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
(Rus)
|
| 卷 22, 编号 1 (2020) |
CLINICAL ONCOLOGY |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
(Rus)
|
| 卷 22, 编号 4 (2020) |
CLINICAL ONCOLOGY |
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Activation of the PI3K-AKT-mTOR cascade in uterine leiomyosarcoma: a retrospective study of 31 patients |
(Rus)
|
| 卷 23, 编号 3 (2021) |
CLINICAL ONCOLOGY |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib |
(Rus)
|
| 卷 24, 编号 1 (2022) |
CLINICAL ONCOLOGY |
Immuno-morphological characteristics of bone marrow in patients with ovarian cancer |
(Rus)
|
| 卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines |
(Rus)
|
